frontMIND / MOR208C310Active, not recruiting

FRONTMIND

Gender
Women and men
Age
18–80 years
Trial type
Interventional
Line of therapy
all
Phase
Phase III

What is this trial about?

The FRONTMIND study is investigating whether adding an antibody (tafasitamab) and an immunomodulatory agent (lenalidomide) to the current standard of care improves treatment outcomes for aggressive lymphoma (B-NHL).

Detailed description

Rituximab-CHOP immunochemotherapy is the standard treatment for aggressive lymphoma.

Tafasitamab is a novel antibody that targets a specific characteristic of malignant cells. Lenalidomide is a substance that modifies the immune system in various ways, thereby potentially providing better defense mechanisms against tumor cells. Both substances have already been shown to be effective against aggressive lymphoma.

This study is a so-called Phase 3 double-blind study. For you, this means that you will be randomly assigned to receive either treatment with the new substances or a placebo. You will receive the current standard of care regardless of which of the two treatment options you are assigned to.

Trial sites

22 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Aachen AöR

    Pauwelsstrasse 30, 52074 Aachen

    Status unknown

  • Charité – Universitätsmedizin Berlin

    Berlin

    Active, not recruiting

  • Vivantes - Netzwerk fuer Gesundheit GmbH

    Dieffenbachstrasse 1/1, 10967 Berlin

    Status unknown

  • Universitätsklinikum Bonn

    Venusberg-Campus 1, 53127 Bonn

    Active, not recruiting

  • Klinikum Chemnitz gGmbH

    Flemmingstrasse 2, 09116 Chemnitz

    Status unknown

  • Carl-Thiem-Klinikum Cottbus gGmbH

    Thiemstrasse 111, 03048 Cottbus

    Status unknown

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT04824092) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.